Jefferson Awarded Multi-Million Dollar NIH Grant To Create A Center Of Excellence For Autoimmune Diseases
Main Category: Multiple SclerosisAlso Included In: Immune System / Vaccines
Article Date: 11 Dec 2009 - 2:00 PDT
| Patient / Public: | ![]() |
4.5 (12 votes) |
| Healthcare Prof: | ![]() |
The Department of Neurology at Jefferson Hospital for Neuroscience has been awarded a multi-million dollar grant from the National Institutes of Health (NIH) for the creation of a center of excellence to study autoimmune diseases from basic science research to its translation into clinical applications. The five-year grant initially totals over $4 million, but could be as much as $10 million by the end of award period. The center is one of nine in the country and the only one in the Pennsylvania.
"Our priority for this award and center is to translate basic science research into practical, clinical applications in autoimmune diseases," said Abdolmohamad Rostami, M.D. Ph.D., professor and chair of the Department of Neurology at Jefferson Medical College of Thomas Jefferson University; director of the Multiple Sclerosis and Neuroimmunology Research Laboratory; and director of the new center. "Primarily we will be focusing on multiple sclerosis (MS), and systemic lupus erthematosus (SLE), but we will also be investigating many other autoimmune diseases like scleroderma. The center's team will investigate how these diseases are produced, with the ultimate goal of finding new and successful ways to treat them."
Currently, Dr. Rostami is investigating the role of Th17 cells, a pro-inflammatory T-cell subset, in MS and ways to suppress these cells in hope of finding better treatments for the disease. His laboratory has shown that interkeukin-27, a cytaline produced by T-cells, can suppress Th17 cells. They have also shown that IL-27 can block the onset or reverse the disease in animals with MS-like disorder. "It appears that one of the ways that recovery from an MS exacerbation occurs is that part of the immune system is shut off, suppressing the immune response in the brain. IL-27 through suppression of Th17 cells appears to be crucial in this process," said Dr. Rostami.
Other researchers of the Autoimmune Diseases Center of Excellence at Jefferson are: Sergio Jimenez, M.D., professor, Department of Dermatology & Cutaneous Biology, director, Scleroderma Center, and co-director, Jefferson Institute of Molecular Medicine; Timothy Manser, Ph.D., professor and chair of the Department of Microbiology & Immunology; Thomas Leist, M.D., Ph.D., associate professor, Department of Neurology; Guang-Xian Zhang, M.D., Ph.D, research associate professor, Department of Neurology; Bogoljub Ciric, Ph.D., research assistant professor, Department of Neurology; and Ziaur Rahman, Ph.D., research assistant professor, Department of Microbiology & Immunology.
Source: Ed Federico
Thomas Jefferson University
Visit our multiple sclerosis section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/173644.php>
APA
http://www.medicalnewstoday.com/releases/173644.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




